For tissue data generation and differential analysis, an MS‐based proteomic analysis was conducted in 150 samples [BrM, n = 60; BrM paired noncancerous adjacent tissue (BrM‐NAT), n = 23; Glioma, n = 55; glioma paired noncancerous adjacent tissue (Glioma‐NAT), n = 12]. This evidence concerns the gene BRD2 and central nervous system cancer.